Amy J Johnson

List of Publications by Year in Descending Order

140 papers	14,419 citations	55 h-index	120 g-index
141 ext. papers	16,107 ext. citations	5.3 avg, IF	5.77 L-index

#	Paper	IF	Citations
140	Optimizing extracellular vesicles isolation from chronic lymphocytic leukemia patient plasma and cell line supernatant. *JCI Insight*, **2021**, 6,	9.9	1
139	Modulation of immune checkpoint molecule expression in mantle cell lymphoma. *Leukemia and Lymphoma*, **2019**, 60, 2498-2507	1.9	10
138	PI3K p110 inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression. *Journal of Clinical Investigation*, **2019**, 129, 122-136	15.9	27
137	Targeting PI3K function for amelioration of murine chronic graft-versus-host disease. *American Journal of Transplantation*, **2019**, 19, 1820-1830	8.7	8
136	Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. *Blood*, **2018**, 131, 1910-1919	2.2	267
135	Cancer-Specific Stress and Trajectories of Psychological and Physical Functioning in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia. *Annals of Behavioral Medicine*, **2018**, 52, 287-298	4.5	7
134	Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. *Blood*, **2018**, 132, 1039-1049	2.2	32
133	Cells, cytokines, chemokines, and cancer stress: A biobehavioral study of patients with chronic lymphocytic leukemia. *Cancer*, **2018**, 124, 3240-3248	6.4	16
132	The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. *Cancer Discovery*, **2018**, 8, 1300-1315	24.4	73
131	Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation. *Biochemistry*, **2018**, 57, 3564-3575	3.2	169
130	Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. *Clinical Cancer Research*, **2017**, 23, 1149-1155	12.9	43
129	BTK-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. *Journal of Clinical Oncology* , **2017**, 35, 1437-1443	2.2	245
128	The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. *Clinical Cancer Research*, **2017** , 23, 2831-2841	12.9	88
127	NF-B p50 () contributes to pathogenesis in the E TCL1 mouse model of chronic lymphocytic leukemia. *Blood*, **2017**, 130, 376-379	2.2	11
126	The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia. *Cancer Medicine*, **2017**, 6, 778-787	4.8	12
125	Might broader be better?. *Blood*, **2017**, 130, 239-240	2.2	2
124	Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. *Blood Advances*, **2017**, 1, 1584-1588	7.8	23

123	Ibrutinib treatment improves T cell number and function in CLL patients. *Journal of Clinical Investigation*, **2017**, 127, 3052-3064	15.9	197
122	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. *New England Journal of Medicine*, **2016**, 374, 323-32	59.2	621
121	Inhibitors of Bruton Tyrosine Kinase Reduce Anti-Red Blood Cell Response in a Murine Model of Autoimmune Hemolytic Anemia. *Blood*, **2016**, 128, 1259-1259	2.2	3
120	Interim Results of a Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia. *Blood*, **2016**, 128, 2831-2831	2.2	8
119	The Bruton Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia. *Blood*, **2016**, 128, 3232-3232	2.2	14
118	Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism. *Blood*, **2016**, 128, 3238-3238	2.2	5
117	A Phase 2 Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Llmphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features. *Blood*, **2016**, 128, 4388-4388	2.2	2
116	the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL. *Blood*, **2016**, 128, 55-55	2.2	7
115	Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia. *Oncotarget*, **2016**, 7, 28684-96	3.3	9
114	Near-Tetraploidy Is Strongly Associated with Development of Richter Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. *Blood*, **2016**, 128, 3198-3198	2.2	
113	Exploring the Functional Relevance of BTK Beyond Chronic Lymphocytic Leukemia (CLL) Cells: BTK Expression in Non-Malignant Immune Cells of the Microenvironment Mediates CLL Development and Progression In Vivo. *Blood*, **2016**, 128, 352-352	2.2	1
112	Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma. *PLoS ONE*, **2016**, 11, e0159607	3.7	39
111	Targeting BTK through microRNA in chronic lymphocytic leukemia. *Blood*, **2016**, 128, 3101-3112	2.2	25
110	Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. *Blood*, **2016**, 127, 1117-27	2.2	282
109	A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. *Leukemia and Lymphoma*, **2016**, 57, 2212-5	1.9	10
108	Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. *JAMA Oncology*, **2015**, 1, 80-7	13.4	398
107	Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. *Leukemia Research*, **2015**, 39, 495-500	2.7	41
106	Hypermorphic mutation of phospholipase C, 2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. *Blood*, **2015**, 126, 61-8	2.2	106

105	Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. *Blood*, **2015**, 125, 3128-32	2.2	63
104	Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. *Blood*, **2015**, 125, 2497-506	2.2	529
103	OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. *Blood*, **2015**, 125, 284-95	2.2	15
102	Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. *Blood*, **2015**, 126, 842-50	2.2	111
101	Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. *Blood*, **2015**, 125, 3297-305	2.2	107
100	Targeted therapies in CLL: mechanisms of resistance and strategies for management. *Blood*, **2015**, 126, 471-7	2.2	96
99	Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694. *Journal of Biological Chemistry*, **2015**, 290, 5960-78	5.4	29
98	Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL). *American Journal of Hematology*, **2015**, 90, 327-33	7.1	14
97	Targeting BTK By a microRNA Mechanism in Chronic Lymphocytic Leukemia. *Blood*, **2015**, 126, 1232-1232	2.2	1
96	ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity. *Blood*, **2015**, 126, 2908-2908	2.2	13
95	The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia. *Blood*, **2015**, 126, 2920-2920	2.2	7
94	Ibrutinib Treatment Reduces Both T-Regulatory Cells and B-Regulatory Cell Phenotype in Malignant B Cells in Chronic Lymphocytic Leukemia Patients. *Blood*, **2015**, 126, 2940-2940	2.2	3
93	Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia. *Oncotarget*, **2015**, 6, 2667-79	3.3	35
92	NFkB p50 (Nfkb1) Contributes to Disease in the Eu-TCL1 Mouse Model of Chronic Lymphocytic Leukemia. *Blood*, **2015**, 126, 1248-1248	2.2	
91	The Eμ-Myc/TCL1 Transgenic Mouse As a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing. *Blood*, **2015**, 126, 2752-2752	2.2	3
90	Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. *Lancet Oncology, The*, **2014**, 15, 48-58	21.7	372
89	Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. *New England Journal of Medicine*, **2014**, 370, 2286-94	59.2	800
88	Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. *Journal of Clinical Oncology*, **2014**, 32, 2067-73	2.2	55

87	Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. *Journal of Clinical Oncology*, **2014**, 32, 3039-47	2.2	96
86	A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia. *Leukemia Research*, **2014**, 38, 1025-9	2.7	11
85	Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). *Blood*, **2014**, 123, 1207-13	2.2	144
84	Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. *Blood*, **2014**, 123, 1810-7	2.2	218
83	Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. *Blood*, **2014**, 123, 1957-60	2.2	173
82	IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. *Blood*, **2014**, 124, 3583-6	2.2	79
81	Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. *Journal of Clinical Investigation*, **2014**, 124, 4867-76	15.9	132
80	A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. *Blood*, **2014**, 124, 1987-1987	2.2	13
79	Targeting Interleukin-2-Inducible T-cell Kinase (ITK) in T-Cell Related Diseases. *Postdoc Journal*, **2014**, 2, 1-11		9
78	Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. *Leukemia Research*, **2013**, 37, 1195-9	2.7	23
77	Identification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: a new potential strategy for identification of anti-cancer therapeutics in B-cell malignancies. *Leukemia and Lymphoma*, **2013**, 54, 2685-92	1.9	22
76	Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. *New England Journal of Medicine*, **2013**, 369, 32-42	59.2	1656
75	A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol. *Clinical Cancer Research*, **2013**, 19, 1269-80	12.9	16
74	Genetic heterogeneity of diffuse large B-cell lymphoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 1398-403	11.5	419
73	Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing. *Blood*, **2013**, 122, 3308-16	2.2	40
72	Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. *Blood*, **2013**, 122, 2539-49	2.2	539
71	Ibrutinib (PCI-32765) Antagonizes Rituximab-Dependent NK-Cell Mediated Cytotoxicity. *Blood*, **2013**, 122, 373-373	2.2	8
70	Dinaciclib (SCH 727965) Is a Novel Cyclin-Dependent Kinase (CDK) Inhibitor That Exhibits Activity In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL). *Blood*, **2013**, 122, 871-871	2.2	11

69	Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL).. *Journal of Clinical Oncology*, **2013**, 31, 7014-7014	2.2	16
68	Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease. *PLoS ONE*, **2013**, 8, e76607	3.7	37
67	Changing The Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype. *Blood*, **2013**, 122, 2872-2872	2.2	
66	OSU-T315, An Integrin-Linked Kinase (ILK) Inhibitor, Induces Apoptosis By Targeting B Cell Receptor and CD49d Mediated AKT/ERK Activation In Chronic Lymphocytic Leukemia Cells. *Blood*, **2013**, 122, 2523-2523	2.2	
65	RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans. *Blood*, **2012**, 119, 4708-18	2.2	43
64	The B-cell receptor signaling pathway as a therapeutic target in CLL. *Blood*, **2012**, 120, 1175-84	2.2	291
63	Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. *Blood*, **2012**, 120, 4621-34	2.2	214
62	Pharmacokinetics and tissue disposition of lenalidomide in mice. *AAPS Journal*, **2012**, 14, 872-82	3.7	21
61	Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia. *Clinical Cancer Research*, **2012**, 18, 4013-8	12.9	37
60	ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. *Blood*, **2012**, 120, 1262-73	2.2	80
59	Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. *Cancer Cell*, **2012**, 21, 694-708	24.3	100
58	Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. *Haematologica*, **2012**, 97, 423-7	6.6	17
57	The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Nai ve (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study. *Blood*, **2012**, 120, 189-189	2.2	16
56	Translating PI3K-Delta Inhibitors to the Clinic in Chronic Lymphocytic Leukemia: The Story of CAL-101 (GS1101). *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2012**, 691-4	7.1	7
55	A Phase I Trial of the Intravenous (IV) Hsp90 Inhibitor 17-DMAG (alvespimycin) in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). *Blood*, **2012**, 120, 1800-1800	2.2	
54	The Hsp90 Inhibitor 17-DMAG Increases SOCS3 and Regulates Cytokine Production, Migration and Cell Death in Chronic Lymphocytic Leukemia. *Blood*, **2012**, 120, 1362-1362	2.2	
53	Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL. *Blood*, **2011**, 117, 862-71	2.2	57
52	The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. *Blood*, **2011**, 117, 4323-7	2.2	79

51	AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia. *Blood*, **2011**, 118, 6132-40	2.2	18
50	Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. *Blood*, **2011**, 117, 6287-96	2.2	601
49	CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. *Blood*, **2011**, 117, 591-4	2.2	605
48	Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. *Journal of Clinical Oncology*, **2011**, 29, 3427-34	2.2	69
47	The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study. *Blood*, **2011**, 118, 983-983	2.2	12
46	Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. *PLoS ONE*, **2010**, 5, e13792	3.7	37
45	17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. *Blood*, **2010**, 116, 45-53	2.2	91
44	Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. *Journal of Clinical Oncology*, **2010**, 28, 418-23	2.2	77
43	Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2010**, 51, 27-38	1.9	23
42	Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. *Blood*, **2010**, 115, 2619-29	2.2	99
41	Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. *Blood*, **2010**, 116, 2078-88	2.2	472
40	Response, Progression-Free Survival, and Overall Survival of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities. *Blood*, **2010**, 116, 2456-2456	2.2	1
39	The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. *PLoS ONE*, **2010**, 5, e10941	3.7	44
38	Flavopiridol Treatment of Patients Aged 70 or Older with Refractory or Relapsed Chronic Lymphocytic Leukemia Is Feasible and Not Associated with Adverse Outcome When Compared to Younger Patients. *Blood*, **2010**, 116, 1378-1378	2.2	
37	Phase I Trial of Flavopiridol In Relapsed Myeloma: Brief Response In t(4;14) with Significant Neutropenia. *Blood*, **2010**, 116, 1933-1933	2.2	
36	Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. *Leukemia and Lymphoma*, **2009**, 50, 349-56	1.9	11
35	Epigenetic alterations in a murine model for chronic lymphocytic leukemia. *Cell Cycle*, **2009**, 8, 3663-7	4.7	19
34	Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. *Journal of Clinical Oncology*, **2009**, 27, 6012-8	2.2	195

33	The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. *British Journal of Haematology*, **2009**, 144, 848-55	4.5	36
32	Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. *Leukemia and Lymphoma*, **2009**, 50, 1232-1234	1.9	
31	Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 13433-8	11.5	73
30	Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. *Blood*, **2009**, 113, 2637-45	2.2	138
29	The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. *Blood*, **2009**, 113, 4656-66	2.2	142
28	Mighty mouse. *Blood*, **2009**, 114, 3	2.2	10
27	CAL-101, An Oral p110δ Selective Phosphatidylinositol-3-Kinase (PI3K) Inhibitor for the Treatment of B Cell Malignancies Inhibits PI3K Signaling, Cellular Viability and Protective Signals of the Microenvironment.. *Blood*, **2009**, 114, 286-286	2.2	4
26	Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. *Journal of Clinical Oncology*, **2008**, 26, 2519-25	2.2	135
25	Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. *Blood*, **2008**, 112, 5180-9	2.2	100
24	Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium. *Blood*, **2008**, 111, 3190-9	2.2	48
23	Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma. *Therapeutic Drug Monitoring*, **2008**, 30, 620-7	3.2	26
22	Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. *Journal of Clinical Investigation*, **2008**, 118, 2427-37	15.9	426
21	CAL-101, a Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-Kinase, Effectively Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells Providing a Novel Therapeutic Strategy for the Treatment of This Disease. *Blood*, **2008**, 112, 3165-3165	2.2	4
20	Loss of Id4 Accelerates CLL Progression in TCL1 Mice. *Blood*, **2008**, 112, 3153-3153	2.2	
19	Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia. *Best Practice and Research in Clinical Haematology*, **2007**, 20, 545-56	4.2	25
18	Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia. *Leukemia Research*, **2007**, 31, 1737-40	2.7	13
17	Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia. *British Journal of Haematology*, **2007**, 139, 837-44	4.5	20
16	Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. *Clinical Cancer Research*, **2007**, 13, 2144-50	12.9	102

15	Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. *Blood*, **2007**, 109, 399-404	2.2	335
14	Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).. *Blood*, **2007**, 110, 3104-3104	2.2	2
13	The Plant-Derived Agent Silvestrol Has B-Cell Selective Activity In Vitro in Chronic Lymphocytic Leukemia Patient Cells and In Vivo in the Tcl-1 Mouse Model of CLL.. *Blood*, **2007**, 110, 3123-3123	2.2	1
12	Unacceptable Toxicity of Lenalidomide When Administered to CLL Patients at Higher Doses.. *Blood*, **2007**, 110, 4727-4727	2.2	
11	Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. *Blood*, **2006**, 108, 1334-8	2.2	102
10	Silvestrol, a Rocaglate Derivative from the Indonesian Plant Aglaia foveolata, Has Significant Bcl-2- and p53-Independent Anti-Tumor Activity against Chronic Lymphocytic Leukemia Cells.. *Blood*, **2006**, 108, 2600-2600	2.2	1
9	Flavopiridol Decreases Mcl-1 and Initiates Early Mitochondrial Damage in Chronic Lymphocytic Leukemia (CLL) Cells.. *Blood*, **2006**, 108, 2098-2098	2.2	
8	The Novel Histone Deacetylase Inhibitor OSU-HDAC42 Has Class I and II Histone Deacetylase (HDAC) Inhibitory Activity and Represents a Novel Therapy for Chronic Lymphocytic Leukemia.. *Blood*, **2006**, 108, 2807-2807	2.2	1
7	A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism. *Blood*, **2005**, 105, 2504-9	2.2	62
6	Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. *Cancer Research*, **2004**, 64, 2424-33	10.1	120
5	Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells. *Blood*, **2004**, 103, 1846-54	2.2	57
4	Advances in the therapy of chronic lymphocytic leukemia. *Current Opinion in Hematology*, **2003**, 10, 297-305	3.3	5
3	The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. *Biochemical Journal*, **2002**, 366, 831-7	3.8	130
2	Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. *Journal of the National Cancer Institute*, **2002**, 94, 585-91	9.7	190
1	Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells. *Advances in Enzyme Regulation*, **2001**, 41, 221-35		54